{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:28:38Z","timestamp":1776263318559,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2016YFC0905500, 2016YFC0905503"],"award-info":[{"award-number":["2016YFC0905500, 2016YFC0905503"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Program of Guangdong","doi-asserted-by":"crossref","award":["2017B020227001, 2016A020215084"],"award-info":[{"award-number":["2017B020227001, 2016A020215084"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Program of Guangzhou","award":["201607020031, 201400000001\u20132"],"award-info":[{"award-number":["201607020031, 201400000001\u20132"]}]},{"name":"Medical Scientific Research Foundation of Guangdong Province, China","award":["A2020153"],"award-info":[{"award-number":["A2020153"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00520-024-09035-8","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T04:17:34Z","timestamp":1732594654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The evolving landscape of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: inspiration from cisplatin-based antiemetic and non-antiemetic trials"],"prefix":"10.1007","volume":"32","author":[{"given":"Ya","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"9035_CR1","unstructured":"Food and Drug Administration (1978) Approval summary for cisplatin for metastatic ovarian tumors [Internet]. FDA oncology tools: center for drug evaluation and research.\u00a0Available from:\u00a0https:\/\/web.archive.org\/web\/20080208232952\/http:\/\/www.accessdata.fda.gov\/scripts\/cder\/onctools\/summary.cfm?ID=73. Accessed 19 Dec 1978"},{"key":"9035_CR2","unstructured":"National Comprehensive Cancer Network (2024) Non-small cell lung cancer (Version2.2024).\u00a0Available from:\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 2 Apr 2024"},{"key":"9035_CR3","unstructured":"National Comprehensive Cancer Network (2024) Small cell lung cancer (Version1.2024). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Accessed 5 Apr 2024\u00a0"},{"key":"9035_CR4","unstructured":"National Comprehensive Cancer Network (2024) Ovarian cancer (Version1. 2024). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf . Accessed 15 Apr 2024"},{"key":"9035_CR5","unstructured":"National Comprehensive Cancer Network (2024) Cervical cancer (Version1. 2024). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf. Accessed 12 Apr 2024"},{"key":"9035_CR6","unstructured":"National Comprehensive Cancer Network (2024) Breast cancer (Version2. 2024). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 15 Apr 2024"},{"key":"9035_CR7","unstructured":"National Comprehensive Cancer Network (2024) Bladder cancer (Version1. 2024). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed 15 Apr 2024"},{"issue":"Suppl 1","key":"9035_CR8","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","volume":"19","author":"SM Grunberg","year":"2011","unstructured":"Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013state of the art. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 19(Suppl 1):S43\u2013S47","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"Suppl 1","key":"9035_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/00003495-198300251-00007","volume":"25","author":"RJ Gralla","year":"1983","unstructured":"Gralla RJ (1983) Metoclopramide. A review of antiemetic trials. Drugs 25(Suppl 1):63\u201373","journal-title":"Drugs"},{"issue":"5","key":"9035_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.1991.9.5.721","volume":"9","author":"J Hainsworth","year":"1991","unstructured":"Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G et al (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 9(5):721\u2013728","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"2","key":"9035_CR11","first-page":"89","volume":"1","author":"RM Navari","year":"2003","unstructured":"Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting\u2013two new agents. J Support Oncol 1(2):89\u2013103","journal-title":"J Support Oncol"},{"issue":"2","key":"9035_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"L Zhang","year":"2018","unstructured":"Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D et al (2018) A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol\u202f: Off J Eur Soc Med Oncol 29(2):452\u2013458","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"9","key":"9035_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","volume":"16","author":"BL Rapoport","year":"2015","unstructured":"Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16(9):1079\u20131089","journal-title":"Lancet Oncol"},{"issue":"6","key":"9035_CR14","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol\u202f: Off J Eur Soc Med Oncol 28(6):1260\u20131267","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"3","key":"9035_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.6004\/jnccn.2017.7043","volume":"16","author":"CC O'Sullivan","year":"2018","unstructured":"O\u2019Sullivan CC, Van Houten HK, Sangaralingham LR, Leal AD, Shinde S, Liu H et al (2018) Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy. J Natl Compr Cancer Netw\u202f: JNCCN 16(3):294\u2013299","journal-title":"J Natl Compr Cancer Netw : JNCCN"},{"key":"9035_CR16","doi-asserted-by":"crossref","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356\u20131367","DOI":"10.1056\/NEJMra1515442"},{"issue":"1","key":"9035_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mdj078","volume":"17","author":"F Roila","year":"2006","unstructured":"Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol\u202f: Off J Eur Soc Med Oncol 17(1):20\u201328","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"7","key":"9035_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1200\/JCO.2003.08.118","volume":"21","author":"WC Mertens","year":"2003","unstructured":"Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM et al (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 21(7):1373\u20131378","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"8","key":"9035_CR19","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, Pel\u00e1ez I, Rodr\u00edguez-Lescure \u00c1, Pastorelli D et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol\u202f: Off J Eur Soc Med Oncol 23(8):1986\u20131992","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"6","key":"9035_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.6004\/jnccn.2019.7526","volume":"18","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Ruddy KJ, LeBlanc TW, Nipp RD, Binder G, Sebastiani S et al (2020) What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. Journal of the National Comprehensive Cancer Network\u202f: JNCCN 18(6):676\u2013681","journal-title":"Journal of the National Comprehensive Cancer Network : JNCCN"},{"issue":"1","key":"9035_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00520-010-1079-3","volume":"20","author":"H Burmeister","year":"2012","unstructured":"Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 20(1):141\u2013147","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"2","key":"9035_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00520-017-3866-6","volume":"26","author":"R Clark-Snow","year":"2018","unstructured":"Clark-Snow R, Affronti ML, Rittenberg CN (2018) Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 26(2):557\u2013564","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"11","key":"9035_CR23","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1007\/s00520-019-04697-1","volume":"27","author":"P Dielenseger","year":"2019","unstructured":"Dielenseger P, B\u00f6rjeson S, Vidall C, Young A, Jahn P (2019) Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 27(11):4099\u20134106","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"10","key":"9035_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2217\/fon-2018-0872","volume":"15","author":"M Aapro","year":"2019","unstructured":"Aapro M, Zhang L, Yennu S, LeBlanc TW, Schwartzberg L (2019) Preventing chemotherapy-induced nausea and vomiting with netupitant\/palonosetron, the first fixed combination antiemetic: current and future perspective. Future Oncol (London, England) 15(10):1067\u20131084","journal-title":"Future Oncol (London, England)"},{"issue":"6","key":"9035_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","volume":"19","author":"A Haiderali","year":"2011","unstructured":"Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer 19(6):843\u201351","journal-title":"Support Care Cancer: Off J Multinatl Assoc Support Care Cancer"},{"issue":"4","key":"9035_CR26","doi-asserted-by":"publisher","first-page":"E133","DOI":"10.1188\/12.CJON.E133-E141","volume":"16","author":"PH Viale","year":"2012","unstructured":"Viale PH, Grande C, Moore S (2012) Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 16(4):E133\u2013E141","journal-title":"Clin J Oncol Nurs"},{"key":"9035_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","volume":"722","author":"K Jordan","year":"2014","unstructured":"Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197\u2013202","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"9035_CR28","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s11096-016-0393-3","volume":"38","author":"N Abunahlah","year":"2016","unstructured":"Abunahlah N, Sancar M, Dane F, \u00d6zyavuz MK (2016) Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life. Int J Clin Pharm 38(6):1464\u20131476","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"9035_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JOP.2012.000816","volume":"10","author":"JW Gilmore","year":"2014","unstructured":"Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J et al (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. J Oncol Pract 10(1):68\u201374","journal-title":"J Oncol Pract"},{"key":"9035_CR30","doi-asserted-by":"publisher","first-page":"651879","DOI":"10.1155\/2015\/651879","volume":"2015","author":"PJ Hesketh","year":"2015","unstructured":"Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H (2015) A Review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomiting. Biomed Res Int 2015:651879","journal-title":"Biomed Res Int"},{"issue":"Suppl 1","key":"9035_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26(Suppl 1):5\u20139","journal-title":"Support Care Cancer"},{"issue":"2","key":"9035_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134\u2013142","journal-title":"N Engl J Med"},{"issue":"3","key":"9035_CR33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00520-019-05210-4","volume":"28","author":"AA Alhifany","year":"2020","unstructured":"Alhifany AA, McBride A, Almutairi AR, Cheema E, Shahbar A, Alatawi Y et al (2020) Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis. Support Care Cancer 28(3):1031\u20131039","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-09035-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T16:05:14Z","timestamp":1733760314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-09035-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9035"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-09035-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with approval from the Ethics Committee of Sun Yat-sen University Cancer Center. This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"822"}}